Our models provide uniquely fine-grained characterization of neurological disease progression. For example, by refining the three clinical stages of Alzheimer’s disease (normal, prodromal/MCI, AD) into a more precise biomarker-based picture.
This provides vital new insight into the disease process for biomedical researchers developing putative treatments, pharmaceutical companies translating treatments to market; and clinicians advising patients and care staff on treatment options.
